KALV
KalVista Pharmaceuticals, Inc.
$26.99
+0.15%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusBuy (54%)
Inst. Holders7 funds
Inst. Value$68.7M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 17S
Insider Net $-$2.1M
SEC Reports8
Recent Activity
Jun 8, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 12d ago
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Tria
May 27, 2026
Insider
Yea Christopher sold 33,800 shares
CHIEF DEVELOPMENT OFFICER @ $7.07 ($239.0K)
May 27, 2026
Insider
Yea Christopher sold 33,800 shares
CHIEF DEVELOPMENT OFFICER @ $0.00 ($0.00)
May 27, 2026
Insider
Yea Christopher sold 33,800 shares
CHIEF DEVELOPMENT OFFICER @ $26.78 ($905.2K)
May 26, 2026
SEC
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/
CLUSTER — Impact 5/10
May 19, 2026
SEC
Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.004% of $1.4B market
CLUSTER — Impact 2/10
Apr 29, 2026
SEC
Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash, valuing the company at approximately $1.9 billio
8-K — Impact 8/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEW
165,151 shares ($2.7M)
Price Targets
$28.60
+6.0% upside
Buy
Current $26.99
Low $27.00
Median $27.00
High $35.00
5 analysts
$27.00
$35.00
Analyst Ratings
2Strong Buy
5Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Apr 30, 2026 | Needham | DOWNGRADE | Buy → Hold |
| Mar 26, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 25, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 ▲ +12.4% | $-0.43 — $-0.02 | 8 | |
| Next Q | $-0.23 ▼ -46.8% | $-0.92 — $0.25 | 74% YoY | 8 |
| Current FY | $-0.80 ▲ +23.8% | $-1.70 — $0.59 | 61% YoY | 7 |
| Next FY | $1.20 ▲ +19.0% | $0.10 — $3.81 | 249% YoY | 6 |
Latest Reports
BEARISH
CLUSTER
5/10
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/
May 26, 2026
NEUTRAL
CLUSTER
2/10
Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.004% of $1.4B market
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $40.5M | — |
| MORGAN STANLEY | $11.3M | DOUBLED |
| BANK OF AMERICA CORP | $6.3M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.2M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $2.7M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Yea Christopher | M | $239.0K |
| May 27, 2026 | Yea Christopher | M | $0.00 |
| May 27, 2026 | Yea Christopher | SELL | $905.2K |
| May 26, 2026 | Yea Christopher | SELL | $52.6K |
| May 26, 2026 | Audhya Paul | SELL | $60.0K |
7 institutional holders with $68.7M total value (4,256,402 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,509,020 | $40.5M | 58.9% | — |
| 2 | MORGAN STANLEY | 700,228 | $11.3M | 16.5% | DOUBLED +135.7% |
| 3 | BANK OF AMERICA CORP /DE/ | 389,813 | $6.3M | 9.2% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 324,369 | $5.2M | 7.6% | DOUBLED +183.7% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 165,151 | $2.7M | 3.9% | NEW |
| 6 | FMR LLC | 111,807 | $1.8M | 2.6% | TRIM -30.8% |
| 7 | WELLS FARGO & COMPANY/MN | 56,014 | $904.6K | 1.3% | ADD +50.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 165,151 | — | $2.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 37,244 | 56,014 | +50.4% | $904.6K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 239,629 | 564,856 | +135.7% | $6.9M | 2025-Q3 |
| UBS Group AG | ADD | 272,861 | 454,148 | +66.4% | $5.5M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 113,496 | 321,967 | +183.7% | $3.9M | 2025-Q3 |
| FMR LLC | TRIM | 133,566 | 92,368 | -30.8% | $1.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 25,324 | 37,244 | +47.1% | $453.6K | 2025-Q3 |
| UBS Group AG | TRIM | 507,703 | 272,861 | -46.3% | $3.1M | 2025-Q2 |
| FMR LLC | ADD | 82,896 | 133,566 | +61.1% | $1.5M | 2025-Q2 |
| UBS Group AG | ADD | 374,631 | 507,703 | +35.5% | $5.9M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 186,593 | 48,400 | -74.1% | $558.5K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 13,463 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 43,429 | 374,631 | +762.6% | $3.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 15,622 | 20,165 | +29.1% | $170.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 110,720 | — | $1.3M | 2024-Q3 |
5 unique insiders with 17 transactions. Net insider value: -$2.1M ($0.00 bought, $2.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 33,800 | $7.07 | $239.0K |
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 33,800 | $0.00 | $0.00 |
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 33,800 | $26.78 | $905.2K |
| May 26, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 1,966 | $26.78 | $52.6K |
| May 26, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 2,239 | $26.78 | $60.0K |
| May 26, 2026 | Sweeny Nicole | Chief Commercial Officer | SELL | 1,489 | $26.78 | $39.9K |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 3,125 | $0.00 | $0.00 |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 5,000 | $0.00 | $0.00 |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | M | 5,000 | $0.00 | $0.00 |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 3,125 | $0.00 | $0.00 |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | M | 5,000 | $0.00 | $0.00 |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 5,000 | $0.00 | $0.00 |
| May 22, 2026 | Piekos Brian | Chief Financial Officer | SELL | 1,489 | $26.78 | $39.9K |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | SELL | 1,861 | $26.78 | $49.8K |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 2,685 | $26.78 | $71.9K |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 2,358 | $26.78 | $63.2K |
| May 22, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 10,926 | $26.78 | $292.6K |
| May 21, 2026 | Piekos Brian | Chief Financial Officer | M | 5,000 | $0.00 | $0.00 |
| May 21, 2026 | Piekos Brian | Chief Financial Officer | M | 5,000 | $0.00 | $0.00 |
| May 21, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 3,750 | $0.00 | $0.00 |
| May 21, 2026 | Sweeny Nicole | Chief Commercial Officer | M | 6,250 | $0.00 | $0.00 |
| May 21, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 6,250 | $0.00 | $0.00 |
| May 21, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 6,250 | $0.00 | $0.00 |
| May 21, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 23,250 | $0.00 | $0.00 |
| May 21, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 3,750 | $0.00 | $0.00 |
| May 21, 2026 | Sweeny Nicole | Chief Commercial Officer | M | 6,250 | $0.00 | $0.00 |
| May 21, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 23,250 | $0.00 | $0.00 |
| May 18, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 1,129 | $26.76 | $30.2K |
| May 18, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 1,032 | $26.76 | $27.6K |
| May 18, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 1,108 | $26.76 | $29.7K |
| May 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 2,419 | $0.00 | $0.00 |
| May 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 2,419 | $0.00 | $0.00 |
| May 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 2,419 | $0.00 | $0.00 |
| May 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 2,419 | $0.00 | $0.00 |
| May 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 1,774 | $0.00 | $0.00 |
| May 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | M | 1,774 | $0.00 | $0.00 |
| May 12, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 3,322 | $26.71 | $88.7K |
| May 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 7,120 | $0.00 | $0.00 |
| May 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 7,120 | $0.00 | $0.00 |
| Apr 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 9,550 | $20.22 | $193.1K |
| Apr 17, 2026 | Piekos Brian | Chief Financial Officer | SELL | 1,862 | $20.22 | $37.6K |
| Apr 17, 2026 | Sweeny Nicole | Chief Commercial Officer | SELL | 1,862 | $20.22 | $37.6K |
| Apr 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 2,686 | $20.22 | $54.3K |
| Apr 16, 2026 | Piekos Brian | Chief Financial Officer | M | 6,250 | $0.00 | $0.00 |
| Apr 16, 2026 | Piekos Brian | Chief Financial Officer | M | 6,250 | $0.00 | $0.00 |
| Apr 16, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | M | 6,250 | $0.00 | $0.00 |
| Apr 16, 2026 | Sweeny Nicole | Chief Commercial Officer | M | 6,250 | $0.00 | $0.00 |
| Apr 16, 2026 | Sweeny Nicole | Chief Commercial Officer | M | 6,250 | $0.00 | $0.00 |
| Apr 16, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 20,312 | $0.00 | $0.00 |
| Apr 16, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | M | 20,312 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 5 bearish, 0 mixed, 2 neutral. Avg impact: 5.5/10.
BEARISH
CLUSTER
5/10
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May
May 26, 2026
NEUTRAL
CLUSTER
2/10
Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.
May 19, 2026
BULLISH
8-K
8/10
Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash, valuing the company at appro
Apr 29, 2026
BEARISH
CLUSTER
6/10
KalVista Pharmaceuticals executives Palleiko (CEO) and Piekos (CFO) sold shares worth $231K in aggre
Apr 20, 2026
BEARISH
CLUSTER
6/10
Seven executives at KalVista Pharmaceuticals, including the CEO, CFO, CMO, CDO, and CCO, exercised s
Feb 25, 2026
BEARISH
CLUSTER, CLUSTER
7/10
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a coordinated cluster
Feb 25, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a concentrated 7-day w
Feb 25, 2026
NEUTRAL
CLUSTER
4/10
Two C-suite executives at KalVista Pharmaceuticals — the CFO and Chief Commercial Officer — sold sha
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (54% buy). Based on 13 analysts: 2 strong buy, 5 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$28.60 mean target
+6.0% upside
Buy (3.00)
$27.00 Low
$35.00 High
| Metric | Value |
|---|---|
| Current Price | $26.99 |
| Target Low | $27.00 |
| Target Mean | $28.60 |
| Target Median | $27.00 |
| Target High | $35.00 |
| # Analysts | 5 |
| Recommendation | Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.43 | $-0.02 | — | +12.4% | 4↑ 2↓ | $0.0B | — | 8 |
| Next Q 2026-09-30 |
$-0.23 | $-0.92 | $0.25 | 74.5% | -46.8% | 4↑ 1↓ | $0.1B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-0.80 | $-1.70 | $0.59 | 60.5% | +23.8% | 6↑ 1↓ | $0.2B | 320.0% | 7 |
| Next FY 2027-12-31 |
$1.20 | $0.10 | $3.81 | 249.3% | +19.0% | 3↑ 2↓ | $0.3B | 59.7% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.260 | |
| 7d ago | $-0.260 | |
| 30d ago | $-0.297 | +0.037 |
| 60d ago | $-0.379 | +0.119 |
| 90d ago | $-0.384 | +0.124 |
4 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 30, 2026 | Needham | DOWNGRADE | Buy | Hold |
| Mar 26, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 25, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 6 | 0 | 0 | 54% | |
| May 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
Clinical Trial
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Phase Phase 3 — COMPLETED
Jun 8, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 12d ago
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Sponsor: KalVista Pharmaceuticals, Ltd.
Phase: P
Jun 5, 2026
Clinical Trial
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Phase Phase 3 — COMPLETED
Jun 5, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 9d ago
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
May 27, 2026
short_volume
Short Volume: KALV — 72.0% short (0.5M / 0.8M)
Short: 544,184 | Exempt: 84,637 | TRF Vol: 755,936 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: KALV — 55.7% short (0.3M / 0.6M)
Short: 313,980 | Exempt: 945 | TRF Vol: 563,604 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: KALV — 21,201 shares ($0.6M) failed to deliver
Settlement: 20260513, Price: $26.73, FTD Value: $566,702.73, KALVISTA PHARMACEUTICALS INC C
May 6, 2026
Clinical Trial
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
Phase Phase 2 — TERMINATED
May 6, 2026
short_interest
FTD: KALV — 27,035 shares ($0.7M) failed to deliver
Settlement: 20260506, Price: $26.71, FTD Value: $722,104.85, KALVISTA PHARMACEUTICALS INC C
Apr 30, 2026
short_interest
FTD: KALV — 125,753 shares ($3.4M) failed to deliver
Settlement: 20260430, Price: $26.67, FTD Value: $3,353,832.51, KALVISTA PHARMACEUTICALS INC C
Apr 23, 2026
short_volume
Short Volume: KALV — 88.1% short (1.0M / 1.1M)
Short: 1,013,537 | Exempt: 0 | TRF Vol: 1,149,831 | Short Ratio: 88.1% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_interest
FTD: KALV — 189,118 shares ($3.7M) failed to deliver
Settlement: 20260417, Price: $19.56, FTD Value: $3,699,148.08, KALVISTA PHARMACEUTICALS INC C
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Sponsor: KalVista Pharmaceuticals, Ltd.
Phase: P
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
Apr 7, 2026
short_interest
FTD: KALV — 163,514 shares ($3.3M) failed to deliver
Settlement: 20260407, Price: $20.19, FTD Value: $3,301,347.66, KALVISTA PHARMACEUTICALS INC C
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Sponsor: KalVista Pharmaceuticals, Ltd.
Phase: P
Apr 6, 2026
short_interest
FTD: KALV — 184,602 shares ($3.7M) failed to deliver
Settlement: 20260406, Price: $19.90, FTD Value: $3,673,579.8, KALVISTA PHARMACEUTICALS INC C
Apr 1, 2026
Clinical Trial
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Phase Phase 3 — COMPLETED